Agile Sciences Announces Issuance of U. S. Patent Covering Use of the Company’s Proprietary Agilyte® Compounds in Agriculture

Share Article

Agile Sciences broadens its Intellectual Property portfolio with new U. S. patent

Agile Sciences announced today that it has been issued its third U.S. patent related to the Company’s proprietary Agilyte® compounds. U. S. Patent No. 12/324,246 entitled, “Inhibition of Biofilms in Plants with Imidazole Derivatives,” was issued on October 4, 2012. This is the first patent issuance that focuses specifically on the agricultural field of use for Agile Sciences’ compounds.

Agile Sciences is developing its proprietary Agilyte® compounds to enhance the biocidal activity of bactericides and fungicides used in agriculture. The Agilyte® compounds are expected to act as “resistance breakers” that restore susceptibility to pathogens that have developed resistance to current market-leading biocidal products.

Dr. Eva Garland, Agile Sciences’ Vice President of Research and Development, commented: “Fungal and bacterial diseases result in devastating crop losses on a global scale. The Agilyte® compounds have demonstrated the ability to enhance current treatment regimens so that these diseases may be controlled more effectively.”

Dr. John Cavanagh, Agile Sciences’ co-founder and William Neal Reynolds Distinguished Professor of Molecular and Structural Biochemistry at North Carolina State University, added, “This patent provides a key addition to Agile Sciences’ intellectual property portfolio. Agile Sciences is particularly pleased to have strengthened our IP position in agriculture, which represents a substantial market opportunity for our unique technology."

About Agile Sciences:
Agile Sciences is headquartered in Raleigh, North Carolina. The company was founded in 2007 to addresses environmental and health issues caused by microbes, including biofilms and biocide resistance. The Company’s Agilyte® small molecules enhance the performance of microbicides and antibiotics toward fungal and bacterial pathogens. For additional information, please visit:

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Keith Stoneback
CEO, Agile Sciences
(919) 457-3308
Email >
Visit website